Recent advances in the development of live, attenuated bacterial vectors

Kenneth L. Roland, Steven A. Tinge, Kevin P. Killeen, Sims K. Kochi

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Over the last quarter century, scientific advances have created new tools and technologies to improve the safety and efficacy of vaccines. These improvements are spurred by social and commercial needs to enhance existing vaccines or to create new ones against an expanding spectrum of diseases. Vaccines based on live, attenuated, pathogenic bacteria were originally developed to prevent infection by homologous pathogens. More recently, strategies have been developed to use these bacterial vaccines as vectors to deliver a variety of protective, vaccine antigens via the mucosal route. These approaches are being developed to protect not only against heterologous microbial infections, but also against non-traditional threats such as biowarfare and cancer. These strategies and their application to the recent development of delivery systems for use in humans will be discussed.

Original languageEnglish (US)
Pages (from-to)62-72
Number of pages11
JournalCurrent Opinion in Molecular Therapeutics
Volume7
Issue number1
StatePublished - Feb 2005
Externally publishedYes

Fingerprint

Vaccines
Bacterial Vaccines
Infection
Technology
Bacteria
Safety
Antigens
Neoplasms

Keywords

  • Bacterial vaccine
  • Bacterial vector
  • Biological weapon
  • Cancer vaccine
  • Gene delivery

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Roland, K. L., Tinge, S. A., Killeen, K. P., & Kochi, S. K. (2005). Recent advances in the development of live, attenuated bacterial vectors. Current Opinion in Molecular Therapeutics, 7(1), 62-72.

Recent advances in the development of live, attenuated bacterial vectors. / Roland, Kenneth L.; Tinge, Steven A.; Killeen, Kevin P.; Kochi, Sims K.

In: Current Opinion in Molecular Therapeutics, Vol. 7, No. 1, 02.2005, p. 62-72.

Research output: Contribution to journalArticle

Roland, KL, Tinge, SA, Killeen, KP & Kochi, SK 2005, 'Recent advances in the development of live, attenuated bacterial vectors', Current Opinion in Molecular Therapeutics, vol. 7, no. 1, pp. 62-72.
Roland, Kenneth L. ; Tinge, Steven A. ; Killeen, Kevin P. ; Kochi, Sims K. / Recent advances in the development of live, attenuated bacterial vectors. In: Current Opinion in Molecular Therapeutics. 2005 ; Vol. 7, No. 1. pp. 62-72.
@article{34a82f9b51014a19a13a694b9bbc2f7f,
title = "Recent advances in the development of live, attenuated bacterial vectors",
abstract = "Over the last quarter century, scientific advances have created new tools and technologies to improve the safety and efficacy of vaccines. These improvements are spurred by social and commercial needs to enhance existing vaccines or to create new ones against an expanding spectrum of diseases. Vaccines based on live, attenuated, pathogenic bacteria were originally developed to prevent infection by homologous pathogens. More recently, strategies have been developed to use these bacterial vaccines as vectors to deliver a variety of protective, vaccine antigens via the mucosal route. These approaches are being developed to protect not only against heterologous microbial infections, but also against non-traditional threats such as biowarfare and cancer. These strategies and their application to the recent development of delivery systems for use in humans will be discussed.",
keywords = "Bacterial vaccine, Bacterial vector, Biological weapon, Cancer vaccine, Gene delivery",
author = "Roland, {Kenneth L.} and Tinge, {Steven A.} and Killeen, {Kevin P.} and Kochi, {Sims K.}",
year = "2005",
month = "2",
language = "English (US)",
volume = "7",
pages = "62--72",
journal = "Current Opinion in Molecular Therapeutics",
issn = "1464-8431",
publisher = "Current Drugs Ltd.",
number = "1",

}

TY - JOUR

T1 - Recent advances in the development of live, attenuated bacterial vectors

AU - Roland, Kenneth L.

AU - Tinge, Steven A.

AU - Killeen, Kevin P.

AU - Kochi, Sims K.

PY - 2005/2

Y1 - 2005/2

N2 - Over the last quarter century, scientific advances have created new tools and technologies to improve the safety and efficacy of vaccines. These improvements are spurred by social and commercial needs to enhance existing vaccines or to create new ones against an expanding spectrum of diseases. Vaccines based on live, attenuated, pathogenic bacteria were originally developed to prevent infection by homologous pathogens. More recently, strategies have been developed to use these bacterial vaccines as vectors to deliver a variety of protective, vaccine antigens via the mucosal route. These approaches are being developed to protect not only against heterologous microbial infections, but also against non-traditional threats such as biowarfare and cancer. These strategies and their application to the recent development of delivery systems for use in humans will be discussed.

AB - Over the last quarter century, scientific advances have created new tools and technologies to improve the safety and efficacy of vaccines. These improvements are spurred by social and commercial needs to enhance existing vaccines or to create new ones against an expanding spectrum of diseases. Vaccines based on live, attenuated, pathogenic bacteria were originally developed to prevent infection by homologous pathogens. More recently, strategies have been developed to use these bacterial vaccines as vectors to deliver a variety of protective, vaccine antigens via the mucosal route. These approaches are being developed to protect not only against heterologous microbial infections, but also against non-traditional threats such as biowarfare and cancer. These strategies and their application to the recent development of delivery systems for use in humans will be discussed.

KW - Bacterial vaccine

KW - Bacterial vector

KW - Biological weapon

KW - Cancer vaccine

KW - Gene delivery

UR - http://www.scopus.com/inward/record.url?scp=14244264779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14244264779&partnerID=8YFLogxK

M3 - Article

C2 - 15732531

AN - SCOPUS:14244264779

VL - 7

SP - 62

EP - 72

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

SN - 1464-8431

IS - 1

ER -